SAN DIEGO, April 30, 2019 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in two
upcoming investor conferences.
Details of the company's participation are as follows:
- 5th Annual SunTrust Robinson Humphrey Life
Sciences Summit
Details: Viking management will participate
in 1-on-1 meetings
Date: May 8, 2019
Location: Lotte New York Palace Hotel, New York City
- 20th Annual B. Riley FBR Investor
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1 meetings
Time/Date: 11:00 a.m. Pacific on
Thursday, May 23, 2019
Location: Beverly Hilton Hotel, Beverly
Hills, CA
Room: 9
About Viking Therapeutics, Inc.
Viking Therapeutics is
a clinical-stage biopharmaceutical company focused on the
development of novel, orally available, first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders. Viking's research and development
activities leverage its expertise in metabolism to develop
innovative therapeutics designed to improve patients' lives.
The company's clinical programs include VK2809, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the treatment of lipid and metabolic disorders,
including non-alcoholic steatohepatitis (NASH). In a Phase 2
trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-300839958.html
SOURCE Viking Therapeutics, Inc.